· Published by Health Canada · Official notice
| Affected Products | Lot or Serial Number | Model or catalog number |
|---|---|---|
| Quantum Blue Anti-Infliximab | 1107.N | LF-ADIF25 |
Positive, instead of negative, results have been reported by customers for the low control and patient samples for Quantum Blue® Anti-Infliximab production Series 1107. The increased false-positive rate was confirmed internally at Bühlmann. Approximately 80% of low control results and 24% of negative patients' samples are now expected to be false positive.
Recall start date: Jan 17, 2022